Evidence map›Paper›PMID 40279083›Full record

ArticleMolecular diversity2026

Graph-Aware AURALSTM: An Attentive Unified Representation Architecture with BiLSTM for Enhanced Molecular Property Prediction.

Muhammed Ali Pala

Abstract read
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Muhammed Ali PalaDepartment of Electrical and Electronics Engineering, Faculty of Technology, Sakarya University of Applied Sciences, 54050, Sakarya, Turkey. pala@subu.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting molecular properties with high accuracy is essential across scientific fields, from drug discovery and biotechnology to materials science and environmental research. In biomedical sciences, accurate molecular property prediction is crucial for elucidating disease mechanisms, identifying potential drug candidates, and optimising various processes. However, existing approaches, often based on low-dimensional representations, fail to capture the intricate spatial and structural complexities of molecular data. This study introduces a novel hybrid deep learning model, the Graph-Aware AURA-LSTM (Attentive Unified Representation Architecture-Long Short-Term Memory), designed to determine molecular properties with unprecedented accuracy using advanced graphical representations. AURA-LSTM combines multiple Graph Neural Network (GNN) architectures, specifically Graph Convolutional Networks (GCNs), Graph Attention Networks (GATs), and Graph Isomorphism Networks (GINs), in a parallel structure to comprehensively capture the multidimensional structural features of molecules. Within this architecture, GCNs incorporate local structural relationships, GATs apply attention mechanisms to highlight critical structural elements, and GINs capture intricate molecular details through isomorphic distinction, resulting in a richly detailed feature matrix. The feature layer then processes this BiLSTM matrix, which evaluates temporal relationships to enhance molecular feature classification. Evaluated on eight benchmark datasets, AURA-LSTM demonstrated superior performance, consistently achieving over 90% accuracy and outperforming state-of-the-art methods. These results position AURA-LSTM as a robust tool for molecular feature classification, uniquely capable of integrating temporally aware insights from distinct GNN architectures.

Indexed as

Deep LearningNeural Networks, ComputerAlgorithmsBiLSTMDeep learningDrug design and discoveryGraph neural networksMolecular property prediction

Identifiers

PMID40279083
PMCPMC13139236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.